Compare Noble Corporation plc (NE) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Noble Corporation plc vs Twist Bioscience Corp — how do they compare? Noble Corporation plc trades at $44.25 (market cap $6.51B), while Twist Bioscience Corp trades at $123.01 (market cap $7.82B). The key difference: Twist Bioscience Corp is the larger of the two by market cap, and Noble Corporation plc pays a 4.91% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| NE | TWST | |
|---|---|---|
Market Cap | $6.51B | $7.82B |
Sector | Technology | Health |
52-Week High | $54.37 | $124.88 |
52-Week Low | $26.61 | $24.16 |
Enterprise Value | $7.94B | $7.75B |
Dividend Yield | 4.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Noble Corporation (NE) trades at $40.77, up 0.2% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported Q2 2026 earnings of $0.01 per share, missing estimates, while revenue declined to $3.1B in 2026 from $3.3B in 2025. Recent news includes a fraud investigation announcement and new drilling contracts, creating investor uncertainty amid operational challenges.
The outlook remains cautious with analyst consensus at Buy (31%) and a $46 price target offering 13% upside. Key risks include earnings volatility, legal scrutiny, and competitive pressures in offshore drilling. Positive cash flow and dividend payments provide some stability, but execution on new contracts and margin improvement are critical for sustained growth.
Twist Bioscience (TWST) trades at $115.67, up 6.04% in the last session, with bullish technical signals from moving averages and a recent analyst upgrade. Revenue growth is strong, with fiscal 2026 Q3 revenue up 23% year-over-year to $118.4 million, though the company remains unprofitable with negative net income margins. A recent $300 million public offering at $96 per share indicates capital raising for expansion.
The outlook is mixed: robust revenue growth and high analyst buy ratings (78.57%) support upside potential, but persistent losses, cash burn, and high valuation ratios pose significant risks. Investors should weigh growth prospects against financial sustainability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
